AI-generated summary
The authors describe a protocol for a planned double-blind randomized trial of 660 nanometer photobiomodulation for diabetic foot ulcers, comparing three fluence doses against a 904 nanometer comparison arm. The trial has not yet reported results, so the abstract states no findings about whether the therapy works. The study is planned to include 100 patients over 10 weeks.
- Participants
- 100
- Who or what was studied
- Patients with diabetic foot ulcers
- Wavelengths
- 660, 904 nm
- Limits stated in the abstract
- The abstract describes a study protocol only, so no outcomes or efficacy results are reported.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 660 nm, 904 nm
- Energy density (fluence)
- 4 J/cm2, 8 J/cm2, 12 J/cm2, 10 J/cm2
- Power
- 20 W
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Randomized controlled trial, Photobiomodulation therapy, Wavelength, Fluence. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.